Lipidor AB

Lipidor AB

  • Price (EUR)1.15
  • Today's Change0.004 / 0.35%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Aug 05 2021 13:13 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Lipidor AB is a Sweden-based drug delivery company focusing on topical medication. The Company is focused to develop, patent and commercialize formulation concepts and technologies based on lipids. The Company develops product concepts based on AKVANO technology, which represents a dosage form that creates a lipid layer on the skin surface for effective delivery of drugs and skin care treatment. The Company’s cooperation partners include Cerbios-Pharma, which specializes in the development and manufacturing of chemical and biological active pharmaceutical ingredients (APIs), and Aurena Laboratories AB, a manufacturer of bag-on-valve aerosol sprays for the pharmaceutical and medical device industry.

  • Revenue in SEK (TTM)730.00k
  • Net income in SEK-17.69m
  • Incorporated--
  • Employees--
  • Location
    Lipidor ABKarolinska Institutet Science ParkFogdevreten 2SOLNA 171 65SwedenSWE
  • Websitehttp://www.lipidor.se/
More ▼
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.